Athira Pharma Inc

Athira Pharma Inc. a late clinical-stage biopharmaceutical company focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor MET for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020 an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105 an orally available brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents including dihexa the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma Inc. was formerly known as M3 Biotechnology Inc. and changed its name to Athira Pharma Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell Washington.